Current File : /var/www/html/digiprint/public/site/cyykrh/cache/6569c5a478555a5e09f3350855d53c0d
a:5:{s:8:"template";s:9437:"<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="utf-8"/>
<meta content="width=device-width, initial-scale=1.0" name="viewport"/>
<title>{{ keyword }}</title>
<link href="//fonts.googleapis.com/css?family=Open+Sans%3A300%2C400%2C600%2C700%2C800%7CRoboto%3A100%2C300%2C400%2C500%2C600%2C700%2C900%7CRaleway%3A600%7Citalic&subset=latin%2Clatin-ext" id="quality-fonts-css" media="all" rel="stylesheet" type="text/css"/>
<style rel="stylesheet" type="text/css"> html{font-family:sans-serif;-webkit-text-size-adjust:100%;-ms-text-size-adjust:100%}body{margin:0}footer,nav{display:block}a{background:0 0}a:active,a:hover{outline:0}@media print{*{color:#000!important;text-shadow:none!important;background:0 0!important;box-shadow:none!important}a,a:visited{text-decoration:underline}a[href]:after{content:" (" attr(href) ")"}a[href^="#"]:after{content:""}p{orphans:3;widows:3}.navbar{display:none}}*{-webkit-box-sizing:border-box;-moz-box-sizing:border-box;box-sizing:border-box}:after,:before{-webkit-box-sizing:border-box;-moz-box-sizing:border-box;box-sizing:border-box}html{font-size:62.5%;-webkit-tap-highlight-color:transparent}body{font-family:"Helvetica Neue",Helvetica,Arial,sans-serif;font-size:14px;line-height:1.42857143;color:#333;background-color:#fff}a{color:#428bca;text-decoration:none}a:focus,a:hover{color:#2a6496;text-decoration:underline}a:focus{outline:thin dotted;outline:5px auto -webkit-focus-ring-color;outline-offset:-2px}p{margin:0 0 10px}ul{margin-top:0;margin-bottom:10px}.container{padding-right:15px;padding-left:15px;margin-right:auto;margin-left:auto}@media (min-width:768px){.container{width:750px}}@media (min-width:992px){.container{width:970px}}@media (min-width:1200px){.container{width:1170px}}.container-fluid{padding-right:15px;padding-left:15px;margin-right:auto;margin-left:auto}.row{margin-right:-15px;margin-left:-15px}.col-md-12{position:relative;min-height:1px;padding-right:15px;padding-left:15px}@media (min-width:992px){.col-md-12{float:left}.col-md-12{width:100%}}.collapse{display:none} .nav{padding-left:0;margin-bottom:0;list-style:none}.nav>li{position:relative;display:block}.nav>li>a{position:relative;display:block;padding:10px 15px}.nav>li>a:focus,.nav>li>a:hover{text-decoration:none;background-color:#eee}.navbar{position:relative;min-height:50px;margin-bottom:20px;border:1px solid transparent}@media (min-width:768px){.navbar{border-radius:4px}}@media (min-width:768px){.navbar-header{float:left}}.navbar-collapse{max-height:340px;padding-right:15px;padding-left:15px;overflow-x:visible;-webkit-overflow-scrolling:touch;border-top:1px solid transparent;box-shadow:inset 0 1px 0 rgba(255,255,255,.1)}@media (min-width:768px){.navbar-collapse{width:auto;border-top:0;box-shadow:none}.navbar-collapse.collapse{display:block!important;height:auto!important;padding-bottom:0;overflow:visible!important}}.container-fluid>.navbar-collapse,.container-fluid>.navbar-header{margin-right:-15px;margin-left:-15px}@media (min-width:768px){.container-fluid>.navbar-collapse,.container-fluid>.navbar-header{margin-right:0;margin-left:0}}.navbar-brand{float:left;height:50px;padding:15px 15px;font-size:18px;line-height:20px}.navbar-brand:focus,.navbar-brand:hover{text-decoration:none}@media (min-width:768px){.navbar>.container-fluid .navbar-brand{margin-left:-15px}}.navbar-nav{margin:7.5px -15px}.navbar-nav>li>a{padding-top:10px;padding-bottom:10px;line-height:20px}@media (min-width:768px){.navbar-nav{float:left;margin:0}.navbar-nav>li{float:left}.navbar-nav>li>a{padding-top:15px;padding-bottom:15px}.navbar-nav.navbar-right:last-child{margin-right:-15px}}@media (min-width:768px){.navbar-right{float:right!important}}.clearfix:after,.clearfix:before,.container-fluid:after,.container-fluid:before,.container:after,.container:before,.nav:after,.nav:before,.navbar-collapse:after,.navbar-collapse:before,.navbar-header:after,.navbar-header:before,.navbar:after,.navbar:before,.row:after,.row:before{display:table;content:" "}.clearfix:after,.container-fluid:after,.container:after,.nav:after,.navbar-collapse:after,.navbar-header:after,.navbar:after,.row:after{clear:both}@-ms-viewport{width:device-width}html{font-size:14px;overflow-y:scroll;overflow-x:hidden;-ms-overflow-style:scrollbar}@media(min-width:60em){html{font-size:16px}}body{background:#fff;color:#6a6a6a;font-family:"Open Sans",Helvetica,Arial,sans-serif;font-size:1rem;line-height:1.5;font-weight:400;padding:0;background-attachment:fixed;text-rendering:optimizeLegibility;overflow-x:hidden;transition:.5s ease all}p{line-height:1.7;margin:0 0 25px}p:last-child{margin:0}a{transition:all .3s ease 0s}a:focus,a:hover{color:#121212;outline:0;text-decoration:none}.padding-0{padding-left:0;padding-right:0}ul{font-weight:400;margin:0 0 25px 0;padding-left:18px}ul{list-style:disc}ul>li{margin:0;padding:.5rem 0;border:none}ul li:last-child{padding-bottom:0}.site-footer{background-color:#1a1a1a;margin:0;padding:0;width:100%;font-size:.938rem}.site-info{border-top:1px solid rgba(255,255,255,.1);padding:30px 0;text-align:center}.site-info p{color:#adadad;margin:0;padding:0}.navbar-custom .navbar-brand{padding:25px 10px 16px 0}.navbar-custom .navbar-nav>li>a:focus,.navbar-custom .navbar-nav>li>a:hover{color:#f8504b}a{color:#f8504b}.navbar-custom{background-color:transparent;border:0;border-radius:0;z-index:1000;font-size:1rem;transition:background,padding .4s ease-in-out 0s;margin:0;min-height:100px}.navbar a{transition:color 125ms ease-in-out 0s}.navbar-custom .navbar-brand{letter-spacing:1px;font-weight:600;font-size:2rem;line-height:1.5;color:#121213;margin-left:0!important;height:auto;padding:26px 30px 26px 15px}@media (min-width:768px){.navbar-custom .navbar-brand{padding:26px 10px 26px 0}}.navbar-custom .navbar-nav li{margin:0 10px;padding:0}.navbar-custom .navbar-nav li>a{position:relative;color:#121213;font-weight:600;font-size:1rem;line-height:1.4;padding:40px 15px 40px 15px;transition:all .35s ease}.navbar-custom .navbar-nav>li>a:focus,.navbar-custom .navbar-nav>li>a:hover{background:0 0}@media (max-width:991px){.navbar-custom .navbar-nav{letter-spacing:0;margin-top:1px}.navbar-custom .navbar-nav li{margin:0 20px;padding:0}.navbar-custom .navbar-nav li>a{color:#bbb;padding:12px 0 12px 0}.navbar-custom .navbar-nav>li>a:focus,.navbar-custom .navbar-nav>li>a:hover{background:0 0;color:#fff}.navbar-custom li a{border-bottom:1px solid rgba(73,71,71,.3)!important}.navbar-header{float:none}.navbar-collapse{border-top:1px solid transparent;box-shadow:inset 0 1px 0 rgba(255,255,255,.1)}.navbar-collapse.collapse{display:none!important}.navbar-custom .navbar-nav{background-color:#1a1a1a;float:none!important;margin:0!important}.navbar-custom .navbar-nav>li{float:none}.navbar-header{padding:0 130px}.navbar-collapse{padding-right:0;padding-left:0}}@media (max-width:768px){.navbar-header{padding:0 15px}.navbar-collapse{padding-right:15px;padding-left:15px}}@media (max-width:500px){.navbar-custom .navbar-brand{float:none;display:block;text-align:center;padding:25px 15px 12px 15px}}@media (min-width:992px){.navbar-custom .container-fluid{width:970px;padding-right:15px;padding-left:15px;margin-right:auto;margin-left:auto}}@media (min-width:1200px){.navbar-custom .container-fluid{width:1170px;padding-right:15px;padding-left:15px;margin-right:auto;margin-left:auto}} @font-face{font-family:'Open Sans';font-style:normal;font-weight:300;src:local('Open Sans Light'),local('OpenSans-Light'),url(http://fonts.gstatic.com/s/opensans/v17/mem5YaGs126MiZpBA-UN_r8OXOhs.ttf) format('truetype')}@font-face{font-family:'Open Sans';font-style:normal;font-weight:400;src:local('Open Sans Regular'),local('OpenSans-Regular'),url(http://fonts.gstatic.com/s/opensans/v17/mem8YaGs126MiZpBA-UFW50e.ttf) format('truetype')} @font-face{font-family:Roboto;font-style:normal;font-weight:700;src:local('Roboto Bold'),local('Roboto-Bold'),url(http://fonts.gstatic.com/s/roboto/v20/KFOlCnqEu92Fr1MmWUlfChc9.ttf) format('truetype')}@font-face{font-family:Roboto;font-style:normal;font-weight:900;src:local('Roboto Black'),local('Roboto-Black'),url(http://fonts.gstatic.com/s/roboto/v20/KFOlCnqEu92Fr1MmYUtfChc9.ttf) format('truetype')} </style>
</head>
<body class="">
<nav class="navbar navbar-custom" role="navigation">
<div class="container-fluid padding-0">
<div class="navbar-header">
<a class="navbar-brand" href="#">
{{ keyword }}
</a>
</div>
<div class="collapse navbar-collapse" id="custom-collapse">
<ul class="nav navbar-nav navbar-right" id="menu-menu-principale"><li class="menu-item menu-item-type-post_type menu-item-object-post menu-item-169" id="menu-item-169"><a href="#">About</a></li>
<li class="menu-item menu-item-type-post_type menu-item-object-post menu-item-121" id="menu-item-121"><a href="#">Location</a></li>
<li class="menu-item menu-item-type-post_type menu-item-object-post menu-item-120" id="menu-item-120"><a href="#">Menu</a></li>
<li class="menu-item menu-item-type-post_type menu-item-object-post menu-item-119" id="menu-item-119"><a href="#">FAQ</a></li>
<li class="menu-item menu-item-type-post_type menu-item-object-post menu-item-122" id="menu-item-122"><a href="#">Contacts</a></li>
</ul> </div>
</div>
</nav>
<div class="clearfix"></div>
{{ text }}
<br>
{{ links }}
<footer class="site-footer">
<div class="container">
<div class="row">
<div class="col-md-12">
<div class="site-info">
<p>{{ keyword }} 2021</p></div>
</div>
</div>
</div>
</footer>
</body>
</html>";s:4:"text";s:16149:"In a written response, AstraZeneca described the German media reports saying its COVID-19 vaccine was shown to have a very low efficacy in the elderly as “completely incorrect”. However, there are new cautionary guidelines for those under thirty. In the UK, the vaccine has been approved … The primary analysis of the Phase III clinical trials from the UK, Brazil and South Africa, published as a preprint in The Lancet confirmed COVID-19 Vaccine AstraZeneca is safe and effective at preventing COVID-19, with no severe cases and no hospitalisations, more than 22 days after the first dose.. The AstraZeneca COVID-19 vaccine should only be routinely given to … The Oxford-AstraZeneca vaccine is being manufactured locally by the Serum Institute of India under the brand name Covishield. On Wednesday, the WHO stated that even though not much data on the efficacy of the AstraZeneca vaccine among the elderly is available, it still recommends its use for over 65s, based on the available evidence. – Melani Nathan. AstraZeneca denies report vaccine less effective in elderly. The Oxford–AstraZeneca COVID-19 vaccine, codenamed AZD1222, and sold under the brand names Covishield and Vaxzevria among others, is a viral vector vaccine for prevention of COVID-19.Developed by Oxford University and AstraZeneca, it is given by intramuscular injection, using as a vector the modified chimpanzee adenovirus ChAdOx1. News Germany restricts use of AstraZeneca vaccine to over 60s in most cases. Galvez said while there were no set protocols yet for the rollout of the vaccine, some doctors recommended it be given to senior healthcare workers. Coronavirus Australia: Elderly urged to receive AstraZeneca jab as TGA plays down fears Vaccinating the nation: state by state breakdown The AstraZeneca vaccine has … The Vaccine Expert Panel (VEP) has wrapped up its discussions on the use of Sinovac’s COVID-19 vaccine on the elderly amid a shortage of AstraZeneca doses, a member of the panel said Tuesday. AstraZeneca on March 22 announced that its COVID-19 vaccine is 80 per cent effective against the virus among the elderly, and poses no blood clot risks. The TGA is expected to approve the AstraZeneca vaccine sometime in February, with considerations of that jab still ongoing. AstraZeneca sought emergency use … The Oxford/AstraZeneca vaccine induced a stronger cellular immune response in elderly adults than the BioNTech/Pfizer shot, potentially providing more protection against severe Covid-19 and new virus variants.. While most Aussies are ready for the jab, there is one persistent fear over the vaccine. SEOUL, Feb 5 — A panel of South Korean advisers has urged caution over the use of AstraZeneca’s Covid-19 vaccine for people older than 65, citing a lack of data, the food and drug safety ministry said today. Jonathan Pugh, University of Oxford and Julian Savulescu, University of Oxford. He said the move would […] The WHO and UK medicine authority both cleared the AstraZeneca vaccine of blood clot risks – signing off for the vaccine to be safely used across the world. With anti-virus restrictions being tightened worldwide again, … The subject of a sometimes acrimonious row between the EU and Britain, the AstraZeneca Covid-19 vaccine has also fuelled debate over its effectiveness among the elderly… The subject of a sometimes acrimonious row between the EU and Britain, the AstraZeneca Covid-19 vaccine has also fuelled debate over its effectiveness among the elderly. There are fresh concerns about Australia's vaccine rollout after Germany warned against giving the AstraZeneca jab to people aged over 65. Australia has ordered more than 50 … AstraZeneca says vaccine 80% effective for elderly, no blood clot risk. Mr Morrison had announced an extra $1.9 billion for vaccine … … “Setback for vaccine” ran as its top story in print the next day,1 subtitled, “The AstraZeneca vaccine apparently has an effectiveness of only 8% in the elderly. The Oxford/AstraZeneca vaccine induced a stronger cellular immune response in elderly adults than the BioNTech/Pfizer shot, potentially providing more … The AstraZeneca/Oxford COVID-19 vaccine appears to be more than 80 percent effective at preventing severe illness among elderly, at-risk individuals after a single dose, according to … Saturday, February 27, 2021. The public vaccination campaign utilising AstraZeneca’s Covid-19 vaccine will begin on March 23 across the capital’s 14 districts and continue for 15 days with a goal of vaccinating more than 110,000 people aged 60 and over. It is recommended that individuals who receive a first dose of COVID-19 Vaccine AstraZeneca complete the vaccination course with COVID-19 Vaccine AstraZeneca (see section 4.4). The Oxford–AstraZeneca COVID-19 vaccine, codenamed AZD1222, and sold under the brand names Covishield and Vaxzevria among others, is a viral vector vaccine for prevention of COVID-19.Developed by Oxford University and AstraZeneca, it is given by intramuscular injection, using as a vector the modified chimpanzee adenovirus ChAdOx1. This effectiveness rate is based on an analysis of results from participants who had received the 2 dose regimen that will be used in Canada. Infectious disease expert Dr. Rontgene Solante said the VEP is forwarding its recommendation to the Department of Health (DOH). The European Medicines Agency (EMA) has today approved the Oxford-AstraZeneca vaccine for use in adults over 18. Authorities in Germany and France recommended the AstraZeneca-Oxford vaccine not be given to the elderly … A decision to limit use of the vaccine, … “For this AstraZeneca vaccine, we will not propose it to those older than 65,” Macron told TF1 television Tuesday night. AstraZeneca’s Vaccine Works in Older Adults, UK Says. The use of the AstraZeneca may have been temporarily suspended for people younger than 60, but the elderly may still get the British-Swedish jab once the Philippines’ supply is replenished, health authorities said Friday. had “great confidence” in AstraZeneca’s vaccine. News COVID: France allows elderly to get AstraZeneca vaccine. Elderly may still get AstraZeneca vaccine but stocks depleted —FDA, DOH. The AstraZeneca/Oxford Covid-19 vaccine appears to be more than 80 percent effective at preventing severe illness among elderly, at-risk individuals after a single dose, according to preliminary research published Wednesday. Oxford-AstraZeneca Vaccine Effective But Questions Remain for Elderly By . In the UK, the vaccine has been approved for use in adults aged 18 and up, but France, Germany, Sweden and Austria say the vaccine should be prioritised for those under the age of 65. In an interview with la Repubblica on Tuesday, AstraZeneca’s CEO, Pascal Soriot, acknowledged there was “a limited amount of data” on the effects of the vaccine … The subject of a sometimes acrimonious row between the EU and Britain, the AstraZeneca Covid-19 vaccine has also fuelled debate over its effectiveness among the elderly. In a written response, AstraZeneca described the German media reports saying its COVID-19 vaccine was shown to have a very low efficacy in the elderly as "completely incorrect". WASHINGTON (AFP) - AstraZeneca's Covid-19 vaccine is 80 per cent effective at preventing the disease in the elderly and does not increase … The Oxford/AstraZeneca (AZN +0.9%) COVID-19 vaccine candidate is safe and effective, giving good protection, researchers have confirmed in The … Beneficial for the elderly The World Health Organization has officially recommended the Oxford/AstraZeneca vaccine for people over the age of 65 and said it should be used 'without an upper age limit'. Regulators in Europe are at odds over whether the Oxford/AstraZeneca vaccine should be given to the elderly. Regulators in Europe are at odds over whether the Oxford/AstraZeneca vaccine should be given to the elderly. France, Sweden, Poland, Germany, France: Oxford/AstraZeneca Vaccine Not for Elderly Only for those who don't need it. The subject of a sometimes acrimonious row between the EU and Britain, the AstraZeneca Covid-19 vaccine has also fuelled debate over its effectiveness among the elderly… In a reversal of policy, the AstraZeneca vaccine will be offered to people up to the age of 74. Canada's National Advisory Committee on Immunization (NACI) is not recommending the use of AstraZeneca's COVID-19 vaccine in individuals aged 65 … In the UK, the vaccine has been approved … Although the European Medicines Agency recommended the vaccine for adults of all ages last week, several countries have advised against administering the jab to older people. COVID: Poland decides against giving elderly AstraZeneca vaccine. Malaysia says Astrazeneca vaccine safe, will be used on elderly Red carpet glamour returns as stars put on a show at the Academy Awards Oscars watch: 93rd … The numbers came in after phase III trials in the US, as European countries shun AstraZeneca vaccines for fears of blood clots. The Lancet found that a vaccine developed by the University of Oxford and AstraZeneca Plc is safe and effective, more analysis will be needed to see how well it works in people over 55, among those at higher risk from the pandemic. Health Minister Datuk Seri Adham Baba said that individuals aged 60 and above were assessed as most suitable to receive it and that the AstraZeneca vaccine will be used in […] German Health Minister Jens Spahn stressed on Tuesday that European authorities would closely examine all available data before making a determination, but declined to comment on the reports about the vaccine’s alleged poor results among the elderly. (Bloomberg) -- A vaccine developed by the University of Oxford and AstraZeneca Plc provided protection against severe Covid-19 in a peer-reviewed study, though more analysis will be needed to see how well it works in older people, among those at highest risk in the pandemic. Regulators in Europe are at odds over whether the Oxford/AstraZeneca vaccine should be given to the elderly. A panel of South Korean advisers has urged caution over the use of AstraZeneca's COVID-19 vaccine for people older than 65, citing a lack of data, the food and drug safety ministry said on Friday. Regulators in Europe are at odds over whether the Oxford/AstraZeneca vaccine should be given to the elderly. Citing positive high-level results from an interim analysis of clinical trials of its vaccine AZD1222, AstraZeneca on January 25 trashed reports claiming that the pharmaceutical firm is ‘unsure’ about its product’s efficacy among elderly over the age of 65. The AstraZeneca vaccine's effects were observed 14 to 20 days after receipt, reaching 60% effectiveness (95% CI, 41% to 73%) at 28 to 34 days and then rising to 73% (95% CI, 27% to 90%) at 42 days. The Astra-Oxford shot looks less effective than Pfizer-BioNTech vaccine and another from Moderna Inc., which each showed 95% efficacy in trials, but is expected to be cheaper and easier to deploy. Dr Malina said that logistically, the choice of vaccination centres (PPV) also impacted the vaccine registration trend. LONDON (Reuters) - AstraZeneca and Oxford University’s potential COVID-19 vaccine produced a strong immune response in older adults, data published on Thursday showed, with researchers expecting to release late-stage trial results by Christmas. The subject of a sometimes acrimonious row between the EU and Britain, the AstraZeneca Covid-19 vaccine has also fuelled debate over its effectiveness among the elderly… A pair of new findings suggest AstraZeneca’s coronavirus vaccine may be effective for both the protection of the elderly and against a quickly-spreading variant.. Oxford University, co … Meanwhile, Sweden’s health agency said it would not recommend the AstraZeneca vaccine for people over 65. AstraZeneca Vaccine Bookings Open Sunday For Elderly In Selected States By CodeBlue | 21 May 2021 Residents aged 60 years and older in the Klang Valley, Penang, Johor, Kuching, and Miri can register for AstraZeneca’s Covid-19 vaccine from 12pm on May 23 on vaksincovid.gov.my. Oxford-AstraZeneca vaccine recommended for all adults by WHO panel. In the UK, the vaccine has been approved for use in adults aged 18 and up, but France, Germany, Sweden and Austria say the vaccine should be prioritised for those under the age of 65. The Oxford/AstraZeneca vaccine may be authorised only for younger people in Europe, because there is insufficient data on how well it works in the … COVID-19 is caused by a virus called coronavirus (SARS CoV 2). KUALA LUMPUR (May 22): A total of 1.24 million doses of the AstraZeneca vaccine is offered to the elderly in the second round of the vaccination offer, which is open for booking of appointment slots at noon tomorrow.The Covid-19 Immunisation Task Force (CITF) in a statement said today the vaccine injections will be given between June 7 and July 27 for the first dose at eight AstraZeneca … France changed its policy on giving the Oxford-AstraZeneca Covid-19 vaccine to the elderly after mounting evidence of its efficacy in older people.. People between the ages of 65 and 74 with existing health problems can be given the vaccine, French Health Minister Olivier Veran said.. On Friday, British regulators said they had received extra trial data from AstraZeneca that supports their view that the COVID-19 vaccine is effective in the elderly. AstraZeneca-Oxford COVID Vaccine 'Quasi-Ineffective' For Elderly: French President Macron French President Emmanuel Macron on January 29 said that the vaccine developed by AstraZeneca appeared not to be effective for people over 65 years. Several countries had advised against administering the jab to older people due to a lack of data among elderly … This began with the administration of Pfizer-BioNTech’s BNT162b2 vaccine in December 2020 and was soon followed by the rollout of the Oxford-AstraZeneca’s ChAdOx1 vaccine… In a written response, AstraZeneca described the German media reports saying its Covid-19 vaccine was shown to have a very low efficacy in the elderly as "completely incorrect". British regulators have received extra trial data from AstraZeneca that supports their view that the COVID-19 vaccine developed with Oxford University is effective in the elderly, a vaccines official said on Friday. AstraZeneca COVID-19 vaccine shows promise in elderly, trial results by Christmas By Kate Kelland and Alistair Smout, Reuters | Posted - Nov. 19, 2020 at 8:21 a.m. ASTRAZENECA’S coronavirus shots from the World Health Organization-led Covax facility are being considered for elderly healthcare workers, vaccine czar Carlito Galvez Jr. said on Thursday. The Pfizer and Oxford-AstraZeneca vaccines have been "highly effective" in reducing coronavirus infections and severe illness among elderly people in Britain, with a more than 80 per cent reduction in hospitalisation, official data showed Monday. Germany and Sweden joined countries widening guidelines for AstraZeneca Plc’s coronavirus vaccine, saying recent data now support giving the shot to the elderly. The subject of a sometimes acrimonious row between the EU and Britain, the AstraZeneca Covid-19 vaccine has also fuelled debate over its effectiveness among the elderly… German commission may do U-turn on AstraZeneca vaccine for elderly. The recommendation is based on the fact there was a limited number of elderly people included in the originally AstraZeneca clinical trials. In the UK, the vaccine has been approved for use in adults aged 18 and up, but France, Germany, Sweden, and Austria say the vaccine should be prioritized for those under the age of 65. In the UK, the vaccine has been approved … A public health expert is calling for volunteers to help over 5,000 senior citizens who are not tech-savvy to register for the AstraZeneca vaccine. On Monday, authorities sought to reassure elderly residents after a panel of advisers urged caution over the use of the AstraZeneca vaccine for people older than 65 because of a lack of data. ";s:7:"keyword";s:27:"astrazeneca vaccine elderly";s:5:"links";s:886:"<a href="http://digiprint.coding.al/site/cyykrh/how-to-change-youtube-font-size">How To Change Youtube Font Size</a>,
<a href="http://digiprint.coding.al/site/cyykrh/american-marriage-ministries">American Marriage Ministries</a>,
<a href="http://digiprint.coding.al/site/cyykrh/explain-thomson-model-of-atom-class-9">Explain Thomson Model Of Atom Class 9</a>,
<a href="http://digiprint.coding.al/site/cyykrh/dave-barry-year-in-review-2020-boston-globe">Dave Barry Year In Review 2020 Boston Globe</a>,
<a href="http://digiprint.coding.al/site/cyykrh/rabiya-mateo-vital-statistics">Rabiya Mateo Vital Statistics</a>,
<a href="http://digiprint.coding.al/site/cyykrh/which-vaccines-are-available-in-germany">Which Vaccines Are Available In Germany</a>,
<a href="http://digiprint.coding.al/site/cyykrh/funerals-in-philadelphia-during-covid-19">Funerals In Philadelphia During Covid-19</a>,
";s:7:"expired";i:-1;}
Mini Shell